Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verrica Pharmaceuticals Inc.

0.5373
-0.0538-9.10%
Post-market: 0.54680.0095+1.77%18:33 EDT
Volume:391.17K
Turnover:219.20K
Market Cap:49.31M
PE:-0.36
High:0.5900
Open:0.5804
Low:0.5370
Close:0.5911
Loading ...

Company Profile

Company Name:
Verrica Pharmaceuticals Inc.
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
71
Office Location:
44 West Gay Street,Suite 400,West Chester,Pennsylvania,United States
Zip Code:
19380
Fax:
- -
Introduction:
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Directors

Name
Position
Paul B. Manning
Chairman of the Board
Ted White
Chief Executive Officer, President and Director
Matt Davidson
Chief Scientific Officer and Director
Gary Goldenberg
Director
Glenn Oclassen
Director
Jayson Rieger
Director
Mark Prygocki
Director
Sean Stalfort
Director

Shareholders

Name
Position
Ted White
Chief Executive Officer, President and Director
Linda Palczuk
Chief Operating Officer
Chris Degnan
Chief Financial Officer
Joe Bonaccorso
Chief Commercial Officer
Matt Davidson
Chief Scientific Officer and Director
Patrick Burnett
Chief Medical Officer